Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
09/2005
09/01/2005WO2005037995A3 Use of cox-2 inhibitor to prevent t-cell anergy induced by dendritic cell therapy
09/01/2005WO2005004792A3 Mixtures of calcitonin drug-oligomer conjugates and methods of use in pain treatment
09/01/2005WO2004073656A9 Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
09/01/2005WO2004063388A3 Hydroxyphenyl cross-linked macromolecular network and applications thereof
09/01/2005WO2004020405A3 Modified transferrin fusion proteins
09/01/2005WO2003089574A3 Synthetic glyco-lipo-peptides as vaccines
09/01/2005US20050192664 Controlled release endoprosthetic device
09/01/2005US20050192637 Method and apparatus for device controlled gene expression
09/01/2005US20050192434 For use as binder resins and drug delivery agents; bioavailability
09/01/2005US20050192260 Pharmaceutical composition
09/01/2005US20050192242 Therapeutic fusion protein transgenes
09/01/2005US20050192235 Compositions and methods for treating or preventing diseases of body passageways
09/01/2005US20050192233 Composition of matter comprising a lanolin free absorption base and method of making
09/01/2005US20050192232 E.g.,N[(R)-3-dodecanoyloxytetradecanoylamino]-C-aspartic acid, alpha-N-{(4R)-5-hydroxy-4-[(R)-3-hydroxytetradecanoyl- amino]pentyl}amide; grafting antigens to modulate immune response and on a pharmaceutical carrier or antibiotic to enhance therapeutic effect or targetting aqueous conjugate injections
09/01/2005US20050192222 Pharmaceutical preparations and medicine capable of generating and/or containing thrombin
09/01/2005US20050192216 Freeze- or vacuum-dried native Factor VIII composition containing trehalose as a stabilizer and no albumin; may be reconstituted with water or brine for administration to a hemophilic patient by injection; stable at up to 60 degrees C.
09/01/2005US20050191746 Compositions and methods for biodegradable polymer-peptide mediated transfection
09/01/2005US20050191702 Immunoglobulin comprising chemokine receptor binding domain and T cell surface polypeptide for use in prevention and treatment of nervous system, skin, diabetes, graft versus host, inflammatory joint and autoimmune diseases
09/01/2005US20050191649 Identifying mutation in oligoadenylate synthetase gene (OAS1); identifying modulators for prevention and treatment of cell proliferative, nervous system and diabetic disorders
09/01/2005US20050191638 Study and interfererance, diagnosis and treatment of polyglutamine using short interfering nucleic acid for treatment of dementia or siezures or muscular dystrophy
09/01/2005US20050191374 Soluble composition containing sporopollenin and the use thereof
09/01/2005US20050191373 Agent for the prevention and/or treatment of septicemia
09/01/2005US20050191366 Process for treating contact dermatitis
09/01/2005US20050191360 Dry powder inhaled PTH formulations; Dipalmitoylphosphatidylcholine and sodium citrate; Parathyroid hormone; maintainence of parathyroid hormone chemical stability
09/01/2005US20050191359 Hydrophilic dispersion; a macrolide antibiotic, donepezil hydrochloride, an azole compound or a taxane; and an amphiphilic polymer which wraps the active compound in a non-crystalline manner to form a nano-sized molecular entity
09/01/2005US20050191346 Two separate chambers, a dividing wall of two layers of material adhered together
09/01/2005US20050191345 Temperature-sensitive liposomal formulation
09/01/2005US20050191344 Imidazolyl Derivatized Distearoylphosphatidylethanolamine for delivery of a polyanionic compound, such as a nucleic acid, polynucleotide, a polysaccharide or a negatively charged protein to a cell
09/01/2005US20050191334 Sustained release device for implantation in the vitreal chamber or the posterior segment of the eye releasing a corticosteroid for an extended period of time
09/01/2005US20050191325 Cushioning wax beads for making solid shaped articles
09/01/2005US20050191323 Pharmaceutical formulations comprising paclitaxel, derivatives and pharmaceutically acceptable salts thereof
09/01/2005US20050191317 Modified virus like particles; antiobesity agents
09/01/2005US20050191314 vaccine comprosing a mixture of A beta oligomers capable of generating an immune response; prophylaxis and treatment of Alzheimer's disease
09/01/2005US20050191310 Novel compositions of saponin adjuvants and excipients
09/01/2005US20050191301 Mammalian EPO mimetic CH1 deleted mimetibodies, compositions, methods and uses
09/01/2005US20050191300 Immunotherapy of autoimmune disorders using antibodies which target B-cells
09/01/2005US20050191292 of reversing cognitive decline by administering a humanized antibody that binds to A beta; particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease or Down's syndrome.
09/01/2005US20050191289 Complexes of immunoglobulins and polysaccharides for oral and transmucosal absorption
09/01/2005US20050191288 Administering to patient before or simultaneously with surgery at least one heparinase enzyme, wherein heparinase enzyme decreases localized inflammatory response in the tissue of the patient
09/01/2005US20050191270 Anti-infectious hydrogel compositions
09/01/2005US20050191267 Mulberry extract; whitening effects for darkened skin through antityrosinase activity, antioxidant and anti-inflammatory properties
09/01/2005US20050191240 Peptide analogs of neurotensin resistant to enzymatic degradation and retain high binding affinity for neurotensin receptors; metal chelating group on one end; replacing Arg8 with Gly(PipAm) ((N-amidinopiperidinyl)glycine) for example; useful for diagnostic and therapeutic purposes
09/01/2005CA2788707A1 Compositions and methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells
09/01/2005CA2556690A1 New complexes
09/01/2005CA2556248A1 Compositions and methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells
09/01/2005CA2556192A1 O,o'-amidomalonate and n,o-amidomalonate platinum complexes
09/01/2005CA2556054A1 Photoreactive compound specifically binding to calcium binding proteins
09/01/2005CA2555772A1 N-terminally monopegylated human growth hormone conjugates, process for their preparation, and methods of use thereof
09/01/2005CA2555661A1 Fusion proteins containing recombinant cytotoxic rnases
09/01/2005CA2555641A1 Drug conjugates
08/2005
08/31/2005EP1568772A2 Human growth hormone variants
08/31/2005EP1568771A2 Human growth hormone variants
08/31/2005EP1568370A1 Topical antibacterial formulations
08/31/2005EP1568366A1 Antifungal and/or antimycotic external preparation for nail comprising neticonazole
08/31/2005EP1568365A1 Warm poultice
08/31/2005EP1568360A1 Liposome
08/31/2005EP1568359A1 Drug delivery system using subconjunctival depot
08/31/2005EP1568283A1 Method of inhibiting acrylamide formation and use thereof
08/31/2005EP1567659A2 Method for continuous, automated blending of solutions from acids and bases
08/31/2005EP1567644A2 Tissue specific genes and gene clusters
08/31/2005EP1567578A1 Polyamino acids functionalized by at least one (oligo)amino acid group and therapeutic uses
08/31/2005EP1567558A2 Aldonic acid esters, methods for producing the same, and methods for producing pharmaceutical active ingredients coupled to polysaccharides or polysaccharide derivatives on free amino groups
08/31/2005EP1567556A2 Recombinant immunotoxin and use in treating tumors
08/31/2005EP1567550A2 Peptide conjugate useful for cell nucleus molecular imaging and tumor therapy
08/31/2005EP1567513A2 High enantiomeric purity dexanabinol for pharmaceutical copositions
08/31/2005EP1567195A1 Dendrimer conjugates for selective of protein aggregates
08/31/2005EP1567194A1 Hypercoiling polymers and their use in cellular delivery
08/31/2005EP1567193A1 Colon cleansing compositions
08/31/2005EP1567188A2 Modified viral particles with immunogenic properties and reduced lipid content useful for treating and preventing infectious diseases
08/31/2005EP1567185A2 Broad spectrum anti-viral therapeutics and prophylaxis
08/31/2005EP1567180A2 Methods of treating cognitive dysfunction by modulating brain energy metabolism
08/31/2005EP1567178A1 Modulators of receptors for parathyrois hormone and parathyroid hormone-related protein
08/31/2005EP1567146A1 Iontophoretic delivery of rotigotine for the treatment of parkinson's disease
08/31/2005EP1567144A2 Method of making, and the use of cytotoxic agents containing elemental selenium
08/31/2005EP1567132A1 Shape-retentive hydrogel particle aggregates and their uses
08/31/2005EP1567127A2 Method of modifying the release profile of sustained release compositions
08/31/2005EP1567126A2 Concentrated liquid valdecoxib composition
08/31/2005EP1567117A1 Materials and methods for preventing and treating microbe-mediated epithelial disorders
08/31/2005EP1567113A2 Antifungal formulations
08/31/2005EP1567014A2 Rapid one-step method for generation of antigen loaded dendritic cell vaccine from precursors
08/31/2005EP1434570B1 Pharmaceutical formulations for the controlled release of 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline
08/31/2005EP1408929B1 Ophthalmic composition containing n-acetylcysteine for the treatment of dry-eye syndrom
08/31/2005EP1401405B1 Oral pharmaceutical compositions with improved bioavailability
08/31/2005EP1392714B1 Steroids as agonists for fxr
08/31/2005EP1365764B1 Oral pharmaceutical composition of cefpodoxime proxetil
08/31/2005EP1259264A4 Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation
08/31/2005EP1173475B1 Fragments of virus protein 2 or 3 of the polyoma virus, used for transporting active ingredients
08/31/2005EP1058542B1 Method for producing encased spherical granular grains comprising prostane derivatives
08/31/2005EP1035833B1 Compositions for nasal administration
08/31/2005EP0973819B1 Non-antigenic branched polymer conjugates
08/31/2005EP0886474B2 Caramels containing a sweetener
08/31/2005EP0721335B1 Mycophenolate mofetil high dose oral suspensions
08/31/2005CN1662930A Actuation indicator for a dispensing device
08/31/2005CN1662586A Hydrous gel and production process and use of the hydrous gel
08/31/2005CN1662506A Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor
08/31/2005CN1662271A Drug delivery assembly
08/31/2005CN1662263A Vitamin-targeted imaging agents
08/31/2005CN1662259A Process for producing block copolymer/drug composite
08/31/2005CN1662252A Acidic insulin preparations with improved stability
08/31/2005CN1662251A Adjuvant enhanced immunotherapy
1 ... 901 902 903 904 905 906 907 908 909 910 911 912 913 914 915 916 917 918 919 920 921 ... 1712